A214610 Stock Overview
Provides on-site diagnostic systems based on Lab-on-a-Chip technology. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
MiCo BioMed Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩1,378.00 |
| 52 Week High | ₩3,310.00 |
| 52 Week Low | ₩1,132.00 |
| Beta | 0.59 |
| 11 Month Change | -28.42% |
| 3 Month Change | -49.62% |
| 1 Year Change | -50.70% |
| 33 Year Change | -81.63% |
| 5 Year Change | -75.68% |
| Change since IPO | -84.18% |
Recent News & Updates
Is MiCo BioMed (KOSDAQ:214610) Using Too Much Debt?
Aug 08
Is MiCo BioMed (KOSDAQ:214610) Using Debt In A Risky Way?
Apr 12Shareholder Returns
| A214610 | KR Medical Equipment | KR Market | |
|---|---|---|---|
| 7D | 4.8% | 9.4% | 2.3% |
| 1Y | -50.7% | 12.3% | -3.8% |
Return vs Industry: A214610 underperformed the KR Medical Equipment industry which returned 12.3% over the past year.
Return vs Market: A214610 underperformed the KR Market which returned -3.8% over the past year.
Price Volatility
| A214610 volatility | |
|---|---|
| A214610 Average Weekly Movement | 17.5% |
| Medical Equipment Industry Average Movement | 7.0% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in KR Market | 11.4% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A214610's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A214610's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 89 | Young Seok Hong | www.micobiomed.com |
MiCo BioMed Co., Ltd. provides on-site diagnostic systems based on Lab-on-a-Chip technology. The company offers molecular diagnostics devices comprising Veri-Q PREP M16 (G2-16TU) system, a device that include membrane to extract nucleic acid using tube; VERI-Q PCR 316, a device to get the result in a short time using plastic chip; VERI-Q PCR 204 (G2-4), a device to deliver the real-time PCR system; PCR and sample prep kits; Veri-Q PCR 316 PB products; and LabChip, sample tube, and pre-filtering column products. It also provides biological chemistry products, including VERI-Q Multi, a cholesterol diagnostic product; VERI-Q Hb Mate and VERI-Q RED, a hemoglobin monitoring system; and VERI-Q PRO, a blood glucose monitoring system.
MiCo BioMed Co., Ltd. Fundamentals Summary
| A214610 fundamental statistics | |
|---|---|
| Market cap | ₩60.03b |
| Earnings (TTM) | -₩30.01b |
| Revenue (TTM) | ₩8.30b |
7.2x
P/S Ratio-2.0x
P/E RatioIs A214610 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A214610 income statement (TTM) | |
|---|---|
| Revenue | ₩8.30b |
| Cost of Revenue | ₩16.75b |
| Gross Profit | -₩8.45b |
| Other Expenses | ₩21.56b |
| Earnings | -₩30.01b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -688.89 |
| Gross Margin | -101.77% |
| Net Profit Margin | -361.41% |
| Debt/Equity Ratio | 68.6% |
How did A214610 perform over the long term?
See historical performance and comparison